Tumour necrosis factor- (TNF-) is an important pro-inflammatory cytokine and has been implicated to play a role in the systemic inflammation of patients with chronic obstructive pulmonary disease (COPD). We conducted a meta-analysis to assess the association between serum TNF- concentration and COPD. PubMed and Embase were searched for eligible studies. Data were extracted and standard mean differences (SMDs) and 95% confidence intervals (CI) were calculated. Thirty-three studies were included in the meta-analysis. The serum TNF- concentrations were higher in patients with stable COPD than healthy controls (SMD = 0.64 pg/ml, 95%CI 0.43, 0.86). COPD patients with normal to high body mass index (BMI) and low BMI had increased TNF- concentration compared with healthy controls (SMD = 1.14 pg/ml, 95%CI 0.36, 1.92; SMD = 1.62 pg/ml, 95%CI 0.89, 2.35 respectively). There was notable significance in serum TNF- level between underweight and normal weight COPD patients (SMD = 0.68, 95%CI 0.43, 0.92). The meta-analysis indicates that patients with stable COPD have higher serum TNF- concentration than healthy controls, and the higher circulating TNF- levels in COPD patients with weight loss may suggest its valuable role in the evaluation of systemic inflammatory responses in stable COPD patients.
CHRONIC obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. It is characterized by persistent airflow limitation that is usually progressive and associated with enhanced chronic inflammatory responses in the airways and lung to noxious particles or gases 1 . The presence of chronic inflammation in both airways and lung parenchyma in COPD is wellknown. Furthermore, there is increasing evidence of systemic inflammation in patients with COPD. Weight loss, muscle wasting and tissue depletion are common features reported in COPD patients, and they are all related to systemic inflammation 2 . Since there is evidence that a number of different inflammatory cells and mediators play a role in the progress of COPD, tumour necrosis factor (TNF)- has become a subject of considerable research at present. TNF- is a pleiotropic cytokine classically described as playing a central role in the pathophysiology of COPD 3 . Moreover, it is involved in the development of muscular abnormalities resulting in loss of skeletal muscle mass and function 4 . An earlier study showed that circulating TNF- levels are significantly higher in COPD patients with weight loss when compared to healthy controls, and that the elevated TNF- levels were correlated with body mass index (BMI) in these patients 5 . A number of studies have also shown that patients with COPD have higher serum concentrations of TNF- than healthy controls [6] [7] [8] [9] . However, results from different studies are not consistent. Some studies showed that serum TNF- concentration is not a good marker in COPD patients with weight loss and that it does not correlate with BMI 10, 11 . Besides, most of the studies undertaken to evaluate this potential relationship are small in size 12, 13 and may lack sufficient statistical data to address this issue adequately. So it still remains controversial whether serum TNF- concentrations are higher in COPD patients than in controls and whether serum TNF- levels are correlated with BMI in patients with COPD. In an effort to overcome these limitations and have a better understanding on the relationship between serum TNF- concentrations and COPD, a systemic review and meta-analysis is necessary. 
Methods

Identification of relevant studies
Inclusion and exclusion criteria
Inclusion criteria were as follows: (1) 
Data extraction
The data were extracted by two investigators (X.X. and J.W.) independently and a consensus was reached on all items. Any disagreement was resolved as described above. The following data were extracted: first author, year of publication, original country, sample size, age, BMI, smoking status, GOLD stages of cases, mean value, SD, SEM and 95% CI of both patients with COPD and healthy subjects. The SEM or 95% CI was transformed into SD using statistical formulas.
Statistical analysis
All the statistics was analysed using Review Manager (version 5.3, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and STATA 12.0 software (Stata Corp LP, College Station, TX, USA). Weighted mean differences (WMDs) were selected to combine statistics. If the difference in mean values was too large or resulted in large heterogeneity, then the standard mean differences (SMDs) were selected. The I 2 statistic was used for quantifying heterogeneity. I 2 < 25%, 25-75% and >75% were considered to indicate low, moderate and high heterogeneity 14 . If the P-value for heterogeneity was >0.05, which showed low heterogeneity (I 2 < 25%), the fixed-effects model was selected. Otherwise, the random-effects model was applied 15 . A two-tailed Z-test was performed to statistically assess differences between healthy subjects and a disease stage, and P < 0.05 was considered statistically significant. In order to assess the BMI effects, subgroup analyses were performed according to the BMI value (COPD with BMI  20 subgroup and COPD with BMI < 20 subgroup). Sensitivity analysis was performed by removing one study each time to see whether the results of the rest would be affected. Egger's test and funnel plot were used to assess the publication bias 16 .
Results
Characteristics of the studies
We identified 832 relevant studies that fit our search strategy. Figure 1 shows the procedure for identifying and selecting eligible studies. Among all the potential studies, 45 duplicate records were removed, leaving 787 articles for screening. Furthermore, 676 articles were excluded by screening titles and abstracts. Two articles were not accessible and we only got 111 for full-text reading. After reading the full text, 78 articles were excluded according to our exclusion criteria. Finally, a total of 33 articles were included for our systematic review and meta-analysis [6] [7] [8] [9] 11, .
Overall meta-analysis
Twelve articles contained subgroup analysis either in COPD patients or healthy controls, and we combined these data using the combination formula wherever possible. The statistical data which could not be combined was regarded as separate studies. Eventually, a total of 33 studies which contained 1696 stable COPD patients and 2804 healthy controls was included. The methodological design in different studies was not the same; therefore, the SMD was selected for quantitative analysis. The studies showed a positive result that the serum levels of TNF- were higher in stable COPD patients than healthy controls (SMD = 0.64 pg/ml, 95% CI 0.43, 0.86, P < 0.00001; I 2 = 86%, P < 0.00001; random effect model, Figure 2 ) [6] [7] [8] [9] 11, .
Subgroup analysis by BMI value
Twelve studies had subgroups according to smoking status, BMI and severity of COPD. We only evaluated TNF- levels by BMI in COPD. BMI was calculated by dividing the weight of the patient by the height squared (weight/height 2 ) using the Outlet index. A BMI of 20 or less was considered low. On the contrary, a BMI of 20 or more was considered normal to high. Seven studies showed data including COPD patients with underweight (BMI < 20) and normal weight (BMI  20) 9, 20, 22, 24, 29, 38, 41 . We compared COPD of normal weight and underweight patients with healthy controls respectively. Both demonstrated that stable COPD patients with normal to high, and low BMI had increased TNF- concentration compared with healthy controls (SMD = 1.14 pg/ml, 95% CI 0.36, 1.92, P = 0.004; I 2 = 86%, P < 0.00001; SMD = 1.62, 95% CI 0.89, 2.35, P < 0.0001; I 2 = 84%, P < 0.00001, random effect model respectively; Figures 3 and  4) . Another subgroup analysis compared COPD patients with BMI  20 and BMI < 20; a notable significance in serum TNF- level was found between them (SMD = 0.68, 95% CI 0.43, 0.92, P < 0.0001; I 2 = 8%, P < 0.37, fixed-effect model).
Sensitivity analysis
We performed a sensitivity analysis for the statistically significant result. Among the overall studies and subgroups, the observed significant result was not materially altered after sequentially excluding each study.
Heterogeneity and publication bias
Egger's test showed a publication bias in the overall meta-analysis (P < 0.00001) and group of COPD with low BMI versus healthy controls (P = 0.006); the shape of the funnel plot was asymmetrical. This may be explained by the presence of a language bias, inflated estimates by a flawed methodological design in smaller studies, and a lack of small trials with opposite results. However, there was no significant evidence of publication bias among COPD with normal to high BMI versus controls (P = 0.201), and COPD with low BMI versus normal to high BMI (P = 0.729). The word 'mixed' means that the subjects (both cases and controls) are composed of smokers and non-smokers. BMI, Body mass index.
Discussion
To our knowledge, the present study is the most comprehensive meta-analysis to assess the relationship between serum TNF- concentration and stable COPD. The metaanalysis demonstrates that serum TNF- level is significantly increased in stable COPD patients compared to healthy controls and BMI is the dominant determinant of circulating TNF- levels in stable COPD patients. TNF- is produced from several cells, including T lymphocytes, mast cells and cells of the airway epithelium, which leads to a shift towards catabolism, resulting in muscle wasting and cachexia 45, 46 . Some observational studies indicated that TNF- levels were significantly elevated in the peripheral blood of patients with COPD [6] [7] [8] [9] and it was associated with BMI 9, 20, 22, 24, 29, 38, 41 . On the other hand, some studies showed no such statistical significance 11, 17, 18 . Therefore, we performed this comprehensive meta-analysis that included the latest data, to examine the association between TNF- levels and stable COPD. Our findings demonstrated that concentrations of serum TNF- were higher in stable COPD than healthy controls and the serum TNF- concentrations may have an association with BMI of COPD patients.
The pooled analysis of 23 studies showed that the levels of serum TNF- were significantly elevated in COPD patients compared to healthy subjects, which suggests that systemic inflammatory activity exists in stable COPD patients. Ten studies showed no significant difference in the values of TNF- between patients and controls 11, 17, 18, 23, 30, 33, 35, 36, 39, 40 , which differs from our results. A previous study showed that TNF- levels are not increased in GOLD 2-4 COPD compared to smokers with normal lung function 47 , which is not congruent with our findings. Shaker et al. 23 reported that TNF- levels are not higher in patients with COPD compared to smokers and non-smokers. Shin et al. 30 also found that the serum TNF- levels were higher in stable COPD patients than the controls, but there was no statistical difference. Obvious heterogeneity was observed in our study, which may be explained by methodological differences among the primary studies, and gender differences and difference in disease severity in the included population.
Thus, TNF- has been shown to play a central role in muscle wasting and weight loss seen in COPD patients 5, 42, 48 . The present meta-analysis involved seven studies which compared the serum TNF- concentrations between COPD patients with lower BMI, and normal to high BMI with healthy subjects. The results show that stable COPD patients with low BMI have increased TNF- concentrations compared with healthy controls. When compared, there is notable significance in serum TNF- levels between COPD patients with BMI  20 and those with BMI < 20. These findings demonstrate that BMI is the dominant determinant of circulating TNF- levels in stable COPD patients, and serum concentrations of the cytokine are higher in COPD patients with weight loss. Furthermore, BMI has been shown to be an independent risk factor for mortality in COPD and has been associated with disease severity 49, 50 . Increased skeletal muscle apoptosis has also been shown to be associated with a lower BMI and reduced exercise tolerance 51 . Moreover, a low BMI has been demonstrated to be a significant predictor of increased mortality 50 . So, it is a meaningful result which highlights the early systemic inflammation in stable COPD patients.
The present meta-analysis indicates that the serum of TNF- levels is increased in underweight COPD patients compared with that with normal weight, and may be a better marker of early inflammation and associated comorbidities. Since TNF- participates directly in inflammation, it may be regarded as a marker of lowgrade systemic inflammation and an additional parameter for risk assessment together with smoking, number of exacerbations, hospitalization rate and mortality rate. More evidence of early interventions might be obtained by synthesizing all these parameters, thus decreasing the risk of possible complications.
There are certain limitations to the present study. First, publication bias has been detected in our study, but it is difficult for us to adjust the impact of these confounding factors such as age, gender and smoking status, which could influence the concentrations of TNF-. Also, the control subjects are not matched for these confounders. It is important to minimize selection bias in future studies. Secondly, some studies had subgroup analysis and we used formulas to calculate these data without considering the confounding factors, which may have led to lower statistical power. Thirdly, some studies were of a small scale, which may affect the power to explore the real association. Lastly, nearly all the included studies were conducted in different institutions. Thus different methods/kits may have been used for measuring the serum TNF- levels, and the detection limit varied, which could inconspicuously influence the data.
Conclusion
The present meta-analysis shows that stable COPD patients have higher serum TNF- concentration than healthy controls, and the circulating TNF- level is associated with the BMI value. Serum concentrations of cytokine are high in COPD patients with weight loss, which suggests that circulating TNF- remains regulated physiologically in stable COPD and varies with the nutritional status. The higher circulating TNF- levels in COPD patients with weight loss may suggest its valuable role in the evaluation of systemic inflammatory responses in stable COPD patients. These findings may partly explain the high prevalence of systemic complications such as cachexia, anorexia and atherosclerosis of COPD. In this regard, more studies with larger sample sizes and those including different stages to evaluate the serum TNF- levels and disease severity are needed to better identify the role of serum TNF-. Whether early interventions would decrease the serum TNF- levels and modify the risk of complications in COPD should also be determined in future studies.
